U.S. License Holder:
Date of License:
PEGASYS (peginterferon alfa-2a) is an inducer of the innate immune response indicated for the treatment of:
Chronic Hepatitis C (CHC): Adult Patients: In combination therapy with other hepatitis C virus drugs for adults with compensated liver disease. Pegasys monotherapy is indicated only if patient has contraindication or significant intolerance to other HCV drugs; Pediatric Patients: In combination with ribavirin for pediatric patients 5 years of age and older with compensated liver disease:
Chronic Hepatitis B (CHB): Adult Patients: Treatment of adults with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) infection who have compensated liver disease and evidence of viral replication and liver inflammation; Pediatric Patients: Treatment of non-cirrhotic pediatric patients 3 years of age and older with HBeAg-positive CHB and evidence of viral replication and elevations in serum alanine aminotransferase (ALT).